Search
sonidegib (Odomzo)
Indications:
- treatment of locally advanced basal cell carcinoma
- indicated for adults for whom surgery or radiation isn't an option, or for basal cell carcinoma recurrence after surgery or radiation
Contraindications:
- pregnancy
Dosage:
- 200 mg PO QD
Adverse effects:
- muscle spasms
- alopecia
- dysgeusia
- fatigue
- nausea/vomiting
- musculoskeletal pain
- diarrhea
- weight loss
- anorexia
- myalgia
- abdominal pain,
- headache
- pain
- pruritus
- rhabdomyolysis
Mechanism of action:
- inhibits Hedgehog pathway
Related
vismodegib (Erivedge)
General
small inhibitory antineoplastic agent (ib drug)
References
- FDA News Release. July 24, 2015
FDA approves new treatment for most common form of advanced
skin cancer.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm